Analysts in Q3 were more focused on medical-surgical challenges, a shift from Q2’s broader interest in oncology and specialty growth. McKesson delivered strong Q3 2025 results, driven by double ...
McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...
The business is divided into four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. Recently, McKesson has emphasized ...
Companies valued at $10 billion or more are generally considered “large-cap” stocks, and McKesson fits this criterion perfectly. It provides pharmaceutical distribution, medical-surgical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results